Bioequivalence Studies: Ensuring Generic Drug Equivalence and Access
*Corresponding Author:Received Date: Jun 12, 2026 / Published Date: Jul 10, 2026
Citation: Reed O (2026) Bioequivalence Studies: Ensuring Generic Drug Equivalence and Access. cpb 15: 584.
Copyright: © 2026 Olivia Reed This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Bioequivalence studies are crucial for demonstrating that generic drug products are therapeutically equivalent to their reference listed drugs. These studies ensure comparable pharmacokinetic profiles, facilitating the market entry of generics and leading to healthcare cost savings and improved patient access. Key aspects include study design, advanced bioanalytical methods, and rigorous statistical analysis, typically employing TOST procedures, to confirm similarity within acceptance limits. Challenges arise with complex dosage forms and narrow therapeutic index drugs, necessitating specialized approaches. Adherence to regulatory guidelines is paramount for scientific integrity and market approval. Understanding food effects and utilizing in vitro-in vivo correlations further refine the assessment process, ensuring predictable drug performance and patient safety
